We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Latest Generation Immunoassay Analyzer to Be Displayed at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016
Print article
Image: The CL-1000i chemiluminescence immunoassay analyzer (Photo courtesy of Shenzhen Mindray Bio-Medical Electronics).
Image: The CL-1000i chemiluminescence immunoassay analyzer (Photo courtesy of Shenzhen Mindray Bio-Medical Electronics).
A large capacity, robust, yet simple-to-use chemiluminescence immunoassay analyzer will be presented at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Shenzhen, China) will have the CL-1000i chemiluminescence immunoassay analyzer on display in Booth 2027 at the Philadelphia expo.

The CL-1000i is a robust yet simple-to-use chemiluminescence immunoassay analyzer. It offers a large capacity of 25 reagents, six sample racks, and supports non-stop replacement of reagents and consumables during testing. By integrating reliable chemiluminescence immunoassay technology with the latest in electrical and intuitive software improvements, CL-1000i reduces the complexity of laboratory operations and enhances diagnostic confidence. Currently Mindray offers 49 immunoassay tests for use with analyzer, with more to come in the near future.

Mindray has been a leading medical devices provider in the areas of patient monitoring and life support, in-vitro diagnostics, and medical imaging system for more than 25 years. In the in vitro diagnostics field, Mindray offers solutions for laboratories with different test volume requirements for hematology, biochemistry, chemiluminescence immunoassay, hemoglobin, flow cytometry, coagulation, and others.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Shenzhen Mindray Bio-Medical Electronics
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.